- Home
- ACEL vs GHRS Comparison
ACEL vs GHRS Comparison
Compare ACEL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACEL | GHRS |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | Ireland |
| Employees | 1600 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.2M | 947.2M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACEL | GHRS |
|---|---|---|
| Price | $11.65 | $22.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.67 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 296.4K | 193.2K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $2.81 | N/A |
| P/E Ratio | $68.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $10.96 |
| 52 Week High | $13.31 | $24.66 |
Technical Indicators
Market Signals| Indicator | ACEL | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 61.36 |
| Support Level | $10.86 | $12.65 |
| Resistance Level | $12.57 | $22.88 |
| Average True Range (ATR) | 0.36 | 1.49 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 34.69 | 58.59 |
Price Performance
Historical ComparisonAbout ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.